Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Interaction and Transport of Methamphetamine and its Primary Metabolites by Organic Cation and Multidrug and Toxin Extrusion Transporters.

Wagner DJ, Sager JE, Duan H, Isoherranen N, Wang J.

Drug Metab Dispos. 2017 Jul;45(7):770-778. doi: 10.1124/dmd.116.074708. Epub 2017 Apr 20.


Quantitative Prediction of CYP3A4 Induction: Impact of Measured, Free, and Intracellular Perpetrator Concentrations from Human Hepatocyte Induction Studies on Drug-Drug Interaction Predictions.

Sun Y, Chothe PP, Sager JE, Tsao H, Moore A, Laitinen L, Hariparsad N.

Drug Metab Dispos. 2017 Jun;45(6):692-705. doi: 10.1124/dmd.117.075481. Epub 2017 Mar 23.


In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.

Sager JE, Tripathy S, Price LS, Nath A, Chang J, Stephenson-Famy A, Isoherranen N.

Biochem Pharmacol. 2017 Jan 1;123:85-96. doi: 10.1016/j.bcp.2016.11.007. Epub 2016 Nov 9.


Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans.

Sager JE, Choiniere JR, Chang J, Stephenson-Famy A, Nelson WL, Isoherranen N.

ACS Med Chem Lett. 2016 Jun 17;7(8):791-6. doi: 10.1021/acsmedchemlett.6b00189. eCollection 2016 Aug 11.


Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro.

Sager JE, Price LS, Isoherranen N.

Drug Metab Dispos. 2016 Oct;44(10):1709-19. doi: 10.1124/dmd.116.072363. Epub 2016 Aug 5.


Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N.

Drug Metab Dispos. 2015 Nov;43(11):1823-37. doi: 10.1124/dmd.115.065920. Epub 2015 Aug 21. Review.


Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.

Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N.

Clin Pharmacol Ther. 2014 Jun;95(6):653-62. doi: 10.1038/clpt.2014.50. Epub 2014 Feb 25.


Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions.

Shirasaka Y, Sager JE, Lutz JD, Davis C, Isoherranen N.

Drug Metab Dispos. 2013 Jul;41(7):1414-24. doi: 10.1124/dmd.113.051722. Epub 2013 Apr 25.

Supplemental Content

Loading ...
Support Center